RBC Capital raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $24.00 (from $22.00) while maintaining a Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments Momentum Movers

Karyopharm Therapeutics (KPTI) Prices 9.15M Share Common Offering at $14.75/ShMay 3, 2018 5:37 AM Karyopharm Therapeutics (KPTI) PT Raised to $25 at Cantor FitzgeraldMay 2, 2018 3:48 AM Karyopharm Therapeutics (KPTI) PT Raised to $21 at WedbushMay 1, 2018 9:59 AM Karyopharm Therapeutics (KPTI) PT Raised to $24 at Leerink PartnersMay 1, 2018 1:34 AM UPDATE: Karyopharm (KPTI) Says Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Achieved 25.4% ORRApril 30, 2018 4:08 PM Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple MyelomaApril 30, 2018 4:05 PM